Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind Study Comparing the Safety and Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, and Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis.

Trial Profile

A Randomized, Double-Blind Study Comparing the Safety and Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, and Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Etanercept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms PRESERVE
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 24 Oct 2018 Results of post-hoc analysis assessing the effect of BMI on response to etanercept treatment in patients with rheumatoid arthritis during open-label treatment and following dose reduction or dosing off in patients who achieved low disease activity or remission using data collected from three randomized trials (PRESERVE, N=834; PRIZE, N=306; T2T, N=489), presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 31 Aug 2018 Biomarkers information updated
    • 16 Jun 2018 Results of post hoc analysis from three randomized trials (PRESERVE, N=834; PRIZE, N=306; T2T, N=489) presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top